Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25883279 | 0.78 | TDP1 (0.54) | POLBTDP1ALDH1A1MAPK8 | |
| SCHEMBL4123313 | 0.76 | SLC6A2 (0.48) | POLBTDP1ALDH1A1CYP3A4UGCG | |
| SCHEMBL1809257 | 0.74 | POLB (0.65) | POLBTDP1 | |
| SCHEMBL15949379 | 0.73 | ALDH1A1 (0.59) | POLBTDP1ALDH1A1 | |
| SCHEMBL10293555 | 0.73 | L3MBTL3 (0.69) | — | |
| SCHEMBL10293598 | 0.73 | L3MBTL3 (0.69) | — | |
| SCHEMBL2143867 | 0.72 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL13696799 | 0.72 | USP30 (0.49) | POLBTDP1MAPK8 | |
| SCHEMBL6202647 | 0.72 | L3MBTL3 (0.67) | POLBGAA | |
| SCHEMBL5909215 | 0.72 | L3MBTL3 (0.67) | POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | POLB 1000/4885TDP1 2129/4885BTK 2494/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | POLB 832/4885TDP1 2833/4885BTK 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.